Find out how Amgen is transforming their antibody discovery and clonal cell line processes with the Berkeley Lights Platform.
Download FilePhilip Tagari, VP Therapeutic Discovery, Amgen, discusses how the Berkeley Lights’ platform has transformed the way Amgen approaches antibody discovery and cell line development.
Learn how to use blocking and binding assays and the Opto Viral Neutralization 1.0 workflow to identify cross-reactive antibodies that may have broad neutralization capacity across the coronavirus family.
Dr. Shireen Khan presents a case study on how ChemPartner has leveraged the Beacon system to rapidly discover cross-reactive antibodies against the GPI-anchored uPA receptor.